Rouviere v. Depuy Orthopaedics, Inc.

District Court, S.D. New York·Decided July 11, 2020·No. 1:18-cv-04814·Unknown

Opinion

USDC SDNY DOCUMENT UNITED STATES DISTRICT COURT ELECTRONICALLY FILED SOUTHERN DISTRICT OF NEW YORK DOC #: 140 DATE FILED: 7/11/2020 Jodi Rouviere, et al., eee

Plaintiffs, 1:18-cv-04814 (UL) (SDA) -against- OPINION AND ORDER Depuy Orthopaedics, Inc. et al., Defendants.

STEWART D. AARON, United States Magistrate Judge: Before the Court is a Letter Motion by Plaintiffs, Jodi Rouviere and Andre Rouviere (collectively, “Plaintiffs”), filed on July 7, 2020, to compel corporate representative(s) of Defendant Howmedica Osteonics Corporation (“Howmedica”), doing business as Stryker Orthopaedics, to appear in person for a deposition, pursuant to Rule 30(b)(6) of the Federal Rules of Civil Procedure, or, in the alternative, to extend the discovery deadline until an in-person deposition of Howmedica’s corporate representative(s) can be conducted. (Pls.’ 7/7/20 Ltr. Mot., ECF No. 135.)* For the following reasons, Plaintiffs’ Letter Motion is DENIED. BACKGROUND This is a medical device product liability case that was commenced on May 31, 2018 arising from injuries allegedly sustained by Plaintiff Jodi Rouviere after receiving a purportedly defective hip implant containing components manufactured by Howmedica and another defendant, Defendant DePuy Orthopaedics, Inc. (“DePuy”). (See Compl., ECF No. 1, 4 1; Am.

In deciding the Letter Motion, the Court has reviewed and considered, in addition to Plaintiffs’ Letter Motion, Howmedica’s Letter Response (Howmedica 7/9/20 Resp., ECF No. 138) and Plaintiffs’ Letter Reply. (Pls.’ 7/10/20 Reply, ECF No. 139.)

Compl., ECF No. 26, ¶ 1.) On January 15, 2019, a Case Management Plan and Scheduling Order was entered (Case Mgt. Plan, ECF No. 58), and discovery commenced in early 2019.2 Plaintiffs’ Letter Motion that currently is before the Court relates to one of several

discovery disputes that has required court intervention in this case. For example, on June 1, 2020, DePuy filed a Letter Motion, pursuant to Rule 26(c) of the Federal Rules of Civil Procedure, for a protective order with respect to certain of Plaintiffs’ Rule 30(b)(6) deposition categories that DePuy contended were improper and burdensome. (DePuy 5/26/20 Ltr. Mot., ECF No. 108.) By Opinion and Order, dated June 10, 2020, this Court granted in part and denied in part DePuy’s

Letter Motion and set forth the disputed categories as to which testimony must be provided by the DePuy corporate representative(s). See Rouviere v. DePuy Orthopaedics, Inc., 2020 WL 2999229, at *6 (S.D.N.Y. June 10, 2020). After the Court issued its Opinion and Order relating to the DePuy Rule 30(b)(6) deposition topics, Howmedica and Plaintiffs reached agreement as to the topics for the Howmedica Rule 30(b)(6) deposition, which were approved by the Court on June 10, 2020. (See 6/10/20 Order, ECF No. 120.)

As of early June 2020, this Court already had granted the parties three extensions of the discovery deadlines. On March 23, 2020, the Court had granted the parties’ joint request for a 90-day extension of the discovery deadlines due to the coronavirus pandemic, which was the third extension. (3/23/20 Order, ECF No. 106.) On June 16, 2020, Plaintiffs filed a Letter Motion for another extension of the discovery deadlines (Pls.’ 6/16/20 Ltr. Mot., ECF No. 124), which

2 Although Rule 5(d)(1)(A) provides that Rule 26(a) disclosures and discovery requests and responses are not to be filed with the Court “until they are used in the proceeding or the court orders filing” (see Fed. R. Civ. P. 5(d)(1)(A)), Plaintiffs filed their Rule 26(a) disclosures and their discovery requests and responses in February and March 2019. (See ECF Nos. 59-64.) Defendants opposed. (Howmedica 6/18/20 Resp., ECF No. 125; DePuy 6/19/20 Resp., ECF No. 126.) By Order, dated June 22, 2020, the Court granted in part and denied in part Plaintiffs’ Letter Motion, and fact discovery is due to close on August 21, 2020. (6/22/20 Order, ECF No. 128.) The

June 22 Order states, as follows: This case has been pending for over two years. In granting a discovery extension in October 2019, the Court stated that “[t]he Parties are encouraged to work diligently to complete discovery within the revised time line as set forth above. Any further extensions will be granted only for good cause shown” (ECF No. 93). Then, in granting another discovery extension in January 2020, the Court stated that “NO FURTHER EXTENSIONS SHALL BE GRANTED EXCEPT IN EXIGENT CIRCUMSTANCES AND THEN ONLY FOR A LIMITED PURPOSE” (ECF No. 100). However, due to the COVID-19 pandemic, the Court in March 2020 granted a request made jointly by all parties for an additional 90-day extension (ECF No. 106). In the circumstances presented, the Court in its discretion grants one final extension. Any discovery not taken in the time periods set forth herein shall be deemed to be waived. Fact depositions shall be completed by August 21, 2020, Plaintiffs’ expert disclosures shall be made by September 21, 2020, the deposition of Plaintiffs’ experts shall be completed by October 21, 2020, Defendants’ expert disclosures shall be made by November 20, 2020, the deposition of Defendants’ experts shall be completed by December 23, 2020 and the parties shall jointly advise the Court whether they would like to be referred for mediation no later than January 15, 2021. Pursuant to Fed. R. Civ. P. 30(b)(3) and (b)(4), all depositions in this action may be taken via telephone, videoconference, or other remote means, and may be recorded by any reliable audio or audiovisual means. This Order does not dispense with the requirements set forth in Fed. R. Civ. P. 30(b)(5), including the requirement that, unless the parties stipulate otherwise, the deposition be “conducted before an officer appointed or designated under Rule 28,” and that the deponent be placed under oath by that officer. For avoidance of doubt, a deposition will be deemed to have been conducted “before” an officer so long as that officer attends the deposition via the same remote means (e.g., telephone conference call or video conference) used to connect all other remote participants, and so long as all participants (including the officer) can clearly hear and be heard by all other participants. (Id.) In their Letter Motion now before the Court, Plaintiffs seek to compel corporate representative(s) of Howmedica to appear in person for deposition, or, in the alternative, to extend the discovery deadline until an in-person deposition of Howmedica’s corporate

representative(s) can be conducted. (Pls.’ 7/7/20 Ltr. Mot. at 1.) Plaintiffs state that they have rented a recreational vehicle and that they intend to drive it from their home state of Florida to New Jersey in order to take the Howmedica deposition in person. (See id. at 1-2.) Howmedica opposes Plaintiffs’ Letter Motion, and argues that Howmedica’s witness and counsel would “place their health at risk by attending an in-person deposition with the Florida plaintiffs,” noting

that all travelers from Florida are subject to 14-day quarantine in New Jersey, and advocate for a video deposition. (See Howmedica Resp.

Free access — add to your briefcase to read the full text and ask questions with AI

Rouviere v. Depuy Orthopaedics, Inc., (S.D.N.Y. 2020).

Rouviere v. Depuy Orthopaedics, Inc. (Rouviere v. Depuy Orthopaedics, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Shockey v. Huhtamaki, Inc.
280 F.R.D. 598 (D. Kansas, 2012)